Current Report Filing (8-k)
November 19 2018 - 3:44PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 15, 2018
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36370
|
|
59-3553710
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
14193 NW 119
th
Terrace
Suite 10
Alachua,
Florida, 32165
(Address of principal executive offices) (Zip Code)
(386)
462-2204
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.07. Submission of Matters to a Vote of Security Holders.
We held our 2019 Annual Meeting of Stockholders on November 15, 2018, at which two proposals were submitted to, and approved by, our stockholders. The
holders of 12,729,365 shares of our common stock were present or represented by proxy at the meeting. The proposals are described in detail in our definitive proxy statement for the 2019 Annual Meeting filed with the Securities and Exchange
Commission on October 16, 2018. The final results for the votes for each proposal are set forth below.
At the annual meeting, each of Scott Koenig
and Ivana Magovcevic-Liebisch was elected as a Class II Director of the Company, to serve a three-year term expiring at the 2022 Annual Meeting of Stockholders. The votes cast in the election of the directors were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Scott Koenig
|
|
|
7,729,005
|
|
|
|
902,820
|
|
|
|
4,097,540
|
|
Ivana Magovcevic-Liebisch
|
|
|
8,203,226
|
|
|
|
428,599
|
|
|
|
4,097,540
|
|
At the annual meeting, our stockholders also approved the proposal to ratify the appointment of Ernst & Young LLP as
our independent registered public accounting firm for our fiscal year ending on June 30, 2019. The votes cast on this proposal were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal
|
|
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
To ratify the appointment of Ernst & Young LLP as the Companys independent
registered public accounting firm for fiscal year 2019
|
|
|
12,690,346
|
|
|
|
19,049
|
|
|
|
19,970
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
APPLIED GENETIC TECHNOLOGIES CORPORATION
|
|
|
By:
|
|
/s/ William A. Sullivan
|
|
|
William A. Sullivan
|
|
|
Chief Financial Officer
|
Date: November 19, 2018
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Applied Genetic Technologies Corporation (NASDAQ): 0 recent articles
More Applied Genetic Technologies Corp News Articles